Research Article
A Seven-Year Retrospective Study on the Surveillance of Hepatitis B in Laos
Table 2
Type of drugs, number, and % on total and triple treatments.
| | Triple therapies | Nb | % of total treatment | % of triple therapy |
| | Cycloferon + Lamivudine + Adefovir | 29 | 4.2% | 63.0% | | Cycloferon + Lamivudine + Pegasys | 3 | 0.4% | 6.5% | | Adefovir + Lamivudine + Tenofovir | 2 | 0.3% | 4.3% | | Adefovir + Tenofovir + Cycloferon | 2 | 0.3% | 4.3% | | Lamivudine + Cycloferon + Ribavirin | 2 | 0.3% | 4.3% | | Adefovir + Cycloferon + Entecavir | 1 | 0.1% | 2.2% | | Adefovir + Cycloferon + Interferon | 1 | 0.1% | 2.2% | | Adefovir + Cycloferon + Pegasys | 1 | 0.1% | 2.2% | | Cycloferon + Interferon + Entecavir | 1 | 0.1% | 2.2% | | Cycloferon + Lamivudine + Entecavir | 1 | 0.1% | 2.2% | | Cycloferon + Lamivudine + Tenofovir | 1 | 0.1% | 2.2% | | Interferon + Cycloferon + Lamivudine | 1 | 0.1% | 2.2% | | Pegasys + Ribavirin + Tenofovir | 1 | 0.1% | 2.2% |
| | Total | 46 | 6.6% | |
|
|
